Intelligent Pharmacy最新文献

{"title":"Real-world safety profile of Levofloxacin: Pharmacovigilance signals, co-medication patterns, and signal validation","authors":"Dan Qin,&nbsp;Ao Gao,&nbsp;Chen Li,&nbsp;Pengzhi Zhao,&nbsp;Mengli Chen","doi":"10.1016/j.ipha.2026.04.005","DOIUrl":"10.1016/j.ipha.2026.04.005","url":null,"abstract":"<div><h3>Objective</h3><div>To characterize epidemiological features and co-medication patterns of Levofloxacin-associated adverse events (AEs) using spontaneous reports and cross-validate pharmacovigilance signals against the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed spontaneous reports for Levofloxacin from the Adverse Drug Reaction Monitoring Center (2020–2024). Patient demographics, regimens, and clinical outcomes were evaluated. Co-medication patterns were identified using association rule mining. Disproportionality analyses were employed for signal detection, with findings cross-validated in FAERS.</div></div><div><h3>Results</h3><div>Among 4,353 reports, 7.14% were severe. The median age was 57 years (male-to-female ratio 1.29:1). Parenteral administration for respiratory, urogenital, and skin infections was predominant. Analysis of 575 co-medication cases yielded 11 significant association rules. The reported AEs manifested primarily as skin and appendages disorders, gastrointestinal disorders, and vascular/coagulation disorders, with 96.76% of patients showing favorable outcomes. At the System Organ Class level, 5 significant signals were detected, with general disorders and administration site conditions showing the strongest signal intensity (ROR = 4.98). At the Preferred Term level, 40 signals were identified, 27 of which were cross-validated in FAERS, including infusion site pruritus (highest intensity, ROR = 39.77).</div></div><div><h3>Conclusions</h3><div>Cross-validation with FAERS confirmed Levofloxacin's established safety profile, characterized by frequent Skin and Appendages Disorders and strong signals for injection site reactions. Notably, co-medication patterns suggest caution when combining Levofloxacin with cephalosporins. Individualized risk assessment and vigilant monitoring are essential to mitigate potential risks.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 261-267"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of intelligent pharmacy technologies in hospitals: A cross-sectional nationwide study","authors":"Wenshuo Jiang,&nbsp;Yuntian Wang,&nbsp;Weizhong Shi,&nbsp;Cao Li,&nbsp;Yongqiang Tang,&nbsp;Zhengzhong Xu,&nbsp;Zhigang Zhao,&nbsp;Xiaolin Yue","doi":"10.1016/j.ipha.2026.05.001","DOIUrl":"10.1016/j.ipha.2026.05.001","url":null,"abstract":"<div><h3>Background</h3><div>Medication errors pose critical threat to patient safety. The implementation of intelligent pharmacy technologies demonstrate great potential to reduce medication risks. This study aimed to investigate the current status of intelligent pharmacy technology implementation in Chinese hospitals.</div></div><div><h3>Methods</h3><div>A nationwide survey was conducted from May 29 to June 10, 2025, covering 1,126 hospitals across China. Based on the intelligent pharmacy products (IPDs) identified through the Delphi method, this survey mainly collected data on current utilization rates of the identified IPD. Pearson's chi-square test was applied to compare usage rates across different hospital types.</div></div><div><h3>Results</h3><div>A total of 36 kinds of commonly used IPDs were identified and classified into six categories: intelligent drug supply (IDS), prescription review (IPR), drug preparation (IDP), drug distribution (IDD), medication consultation (IMC), and medication monitoring systems (IMM). Usage rates of these 6 types of systems varied significantly in hospital of different levels and number of beds (<em>P</em> &lt; 0.001). Hospitals with a higher number of pharmacists per 100 beds (PPB ≥ 7) reported significantly lower utilization rates of IPR, IMC, and IMM systems (<em>P</em> &lt; 0.001). Regionally, eastern coastal provinces such as Zhejiang, Jiangsu, and Shandong demonstrated higher levels of intelligent pharmacy implementation.</div></div><div><h3>Conclusions</h3><div>The implementation of intelligent pharmacy in China was uneven across regions, hospital levels, sizes, and pharmacist numbers. Future development should be supported by policy incentives and tailored to specific clinical needs, ensuring a balanced and sustainable advancement of intelligent pharmacy.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 268-274"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility and readability of large language models’ responses to headache-related inquiries: A comparative evaluation with stratified application recommendations based on Chinese online health communities","authors":"Qiansu Yang,&nbsp;Zhao Dong,&nbsp;Yinglin Yang,&nbsp;Jinyu Liu,&nbsp;Le Cai,&nbsp;Nan Bai,&nbsp;Tianlin Wang","doi":"10.1016/j.ipha.2026.05.003","DOIUrl":"10.1016/j.ipha.2026.05.003","url":null,"abstract":"<div><div>Headache disorders affect a large proportion of the global population, and large language models (LLMs) show potential in the provision of online health information services, with their response accuracy and readability requiring verification. This cross-sectional study used an expert panel of five headache specialists and three clinical neuroscience pharmacists to evaluate the quality and readability of LLM(represented by GPT-5-main) generated responses to 53 headache-related public inquiries paired with responses from physicians and pharmacists from Chinese online health communities (OHC)-Haod (Jan 2020 to Dec 2024) via six evaluation dimensions and the AlphaReadabilityChinese tool, with stratified analyses by inquiry difficulty (Level 1: simple; Level 2: complex). The results showed that LLM responses were significantly longer than responses from physicians and pharmacists (<em>p</em> &lt; 0.001), with a 27.4% mean accuracy for authorship distinction; LLM produced fewer incorrect contents (PR = 0.60, 95% CI = 0.50–0.71) and lower harm risk (PR = 0.85, 95% CI = 0.80–0.91), along with better alignment to medical consensus (PR = 1.63, 95% CI = 1.40–1.90), relevance (PR = 2.32, 95% CI = 1.79–3.00) and completeness (PR = 2.95, 95% CI = 2.31–3.75) than responses from physicians and pharmacists. Stratified analysis indicated that LLM achieved non-inferior health information quality to physicians and pharmacists for Level 1 inquiries (all <em>p</em> &gt; 0.05), and we recommend that Level 2 inquiries be subject to human review to optimize safety and relevance. Responses from physicians and pharmacists were significantly more readable than LLM across multiple metrics (all <em>p</em> &lt; 0.001). In conclusion, for headache-related enquiries, LLM responses were rated more favorably by experts across multiple dimensions within this dataset and can serve as valuable adjuncts to OHC, independently resolving simple enquiries. However, readability improvements are needed for direct public use, and review of physicians and pharmacists is required for complex cases.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 281-288"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: A systematic review and meta-analysis of randomized controlled trials","authors":"Xinrui Hu,&nbsp;Lijuan Qi,&nbsp;Jinbo Du,&nbsp;Yuhan Wang,&nbsp;Yukun Yin","doi":"10.1016/j.ipha.2026.05.005","DOIUrl":"10.1016/j.ipha.2026.05.005","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) constitutes a significant global health challenge. Chemotherapy-induced nausea and vomiting (CINV) severely impact patient quality of life. Current antiemetics, while providing some relief, prove inadequate. Auricular acupressure (AA), originating from traditional Chinese medicine, demonstrates potential in managing CINV; yet, its efficacy and safety in the context of BC chemotherapy are still uncertain.</div></div><div><h3>Methods</h3><div>In compliance with PRISMA 2020 guidelines, we executed a systematic review and meta-analysis, searching PubMed, EMBASE, Cochrane CENTRAL,Web of Science, CNKI, and Wanfang until October 2023. We included randomized controlled trials (RCTs) that compared pure auricular acupressure (AA alone) or AA combined with consistent co-interventions across groups with standard care for BC patients and methodically performed data extraction, risk of bias evaluation, and meta-analysis. To ensure clear attribution of effect, subgroup analyses were performed between AA alone and AA plus other traditional Chinese medicine (TCM) interventions.</div></div><div><h3>Results</h3><div>Thirty-one RCTs involving 2522 participants, predominantly from China, satisfied our inclusion criteria. Notable heterogeneity was detected. Although AA did not markedly decrease acute or delayed vomiting, it significantly enhanced strictly defined complete response (score 0, no symptoms) rates for nausea (RR 1.31; 95% CI 1.16 – 1.47; <em>P</em> &lt; 0.0001) and overall CINV (RR 1.79; 95% CI 1.60 – 2.00; <em>P</em> &lt; 0.0001). Subgroup analysis confirmed that effects were consistent in both AA alone and AA combined with TCM, supporting that AA contributed independently to the improvement. Enhancements were more pronounced with prolonged treatment, higher frequency, and targeted use of specific auricular points.</div></div><div><h3>Conclusions</h3><div>AA may improve the comprehensive management of CINV, specifically nausea, not acute or delayed vomiting - among BC chemotherapy patients. The effect can be primarily attributed to auricular acupressure, as subgroup analysis ruled out confounding from combined TCM interventions. Nonetheless, given the methodological constraints, the reliability of this evidence is provisional. Comprehensive, large-scale RCTs are essential to verify these results.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 297-304"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of influencing factors on the steady-state concentration/dose ratio of vortioxetine based on therapeutic drug monitoring","authors":"Xiaoqian Lan,&nbsp;Hongyan Zhuang,&nbsp;Shuang Bao,&nbsp;Mengxi Niu,&nbsp;Yannan Zang,&nbsp;Fei Jia,&nbsp;Pengfei Li","doi":"10.1016/j.ipha.2026.05.002","DOIUrl":"10.1016/j.ipha.2026.05.002","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the influencing factors of the steady-state concentration/dose ratio (C/D) of vortioxetine and promote individualized and rational use of vortioxetine.</div></div><div><h3>Methods</h3><div>All inpatients who received therapeutic drug monitoring (TDM) of vortioxetine in our hospital from July 2022 to December 2025 were included. Basic information such as gender, age, body mass index (BMI), and <em>CYP2D6</em> genotype, as well as drug treatment information including dosage and concomitant medications, was collected through the electronic medical record system. Data were statistically analyzed using SPSS 23.0 software.</div></div><div><h3>Results</h3><div>A total of 109 patients with measured steady-state blood drug concentrations were included in this study. The steady-state blood concentration of vortioxetine was 22.06 (13.26, 35.34) ng·mL⁻¹, and the median (IQR) C/D value was 1.53 (0.97,2.23) ng·mL⁻¹·mg⁻¹·d. The administered dose explained only 26.3% of the variability in vortioxetine plasma concentrations. Concomitant lamotrigine was associated with a lower C/D ratio in univariate analysis (<em>p</em> &lt; 0.05), but this association did not remain significant in multivariate analysis (<em>p</em> = 0.154).</div></div><div><h3>Conclusions</h3><div>There is a significant inter-individual pharmacokinetic difference in vortioxetine concentration. The potential effect of lamotrigine on vortioxetine C/D ratio requires further investigation, as the univariate finding was not confirmed in multivariate analysis. It is recommended that patients undergo routine therapeutic drug monitoring to ensure the safety and efficacy of vortioxetine use.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 275-280"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Aiyu capsules for chemotherapy-induced leukopenia in cancer patients: A multi-center parallel-group randomized controlled trial","authors":"Lan-yu Chen,&nbsp;Yu-xin Liu,&nbsp;Dong-xin Tang,&nbsp;Yu-ju Bai,&nbsp;Li-kun Liu,&nbsp;Shu-lan Hao,&nbsp;Ji-long Hu,&nbsp;Man Luo,&nbsp;Hai Lan,&nbsp;Ning Xu,&nbsp;Yun-hong Huang,&nbsp;Ying-jie Yang,&nbsp;Xia Yang,&nbsp;Cheng-qiang Zhang,&nbsp;Fan-jie Qu,&nbsp;Yi-hong Wu,&nbsp;Jun Dai,&nbsp;Li Luo,&nbsp;Yi Li,&nbsp;Si Xia,&nbsp;Zhi Zheng","doi":"10.1016/j.ipha.2026.05.004","DOIUrl":"10.1016/j.ipha.2026.05.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study aimed to assess the efficacy and safety of Aiyu capsules, a traditional Chinese medicine (TCM) formulation, in preventing and treating chemotherapy-induced leukopenia, as well as to evaluate their effects on patient-reported quality of life. The findings are intended to provide evidence supporting the adjunctive use of Aiyu capsules for the management of chemotherapy-associated bone marrow suppression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this multicenter, randomized controlled trial, 288 patients diagnosed with colorectal cancer, gastric cancer, lymphoma, or ovarian cancer were recruited from 20 centers, including Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, and the First Affiliated Hospital of Guangzhou University of Chinese Medicine, between May 2022 and February 2025. Participants were allocated in a 1:1 ratio to either the Aiyu capsules group or the control group using a stratified block dynamic randomization approach. Patients in the control group (&lt;em&gt;n&lt;/em&gt; = 144) received standard chemotherapy and placebo therapy, whereas those in the Aiyu capsules group (&lt;em&gt;n&lt;/em&gt; = 144) were administered oral Aiyu capsules beginning three days prior to chemotherapy initiation and continued for 21 consecutive days in conjunction with standard chemotherapy. Hematological parameters were monitored following chemotherapy and during the subsequent treatment cycle. Additional assessments included the utilization rate of granulocyte colony-stimulating factor (G-CSF), quality of life as measured by the Quality of Life Questionnaire-Core 30 (QLQ-C30), TCM syndrome scores, and the incidence and severity of adverse events (AEs) throughout the study period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Patients receiving Aiyu capsules demonstrated significantly greater improvements in quality of life and TCM syndrome scores compared with those receiving chemotherapy alone. At day 21, QLQ-C30 evaluations showed that the median change from baseline in the total score for items 1-28 was −2.50 in the Aiyu capsules group, compared with 0 in the control group (&lt;em&gt;p&lt;/em&gt; &lt; 0.0001), indicating a more pronounced enhancement in overall quality of life. Consistently, the median changes from baseline in global health status and overall quality of life scores were both 1 in the Aiyu capsules group and 0 in the control group (&lt;em&gt;p&lt;/em&gt; &lt; 0.0001). With regard to TCM-related outcomes, reductions in fatigue and palpitations at day 21 were significantly greater in the Aiyu capsules group (&lt;em&gt;p&lt;/em&gt; &lt; 0.005), and the decrease in total TCM syndrome scores was also more substantial (−2 vs. 0, &lt;em&gt;p&lt;/em&gt; = 0.0002). The incidence of severe AEs was lower in the Aiyu capsules group than in the control group. Among all reported AEs, severe AEs accounted for 1.29% in the Aiyu capsules group versus 3.51% in th","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 4","pages":"Pages 289-296"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149033335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in pharmaceutical administration and clinical pharmacy: A comprehensive review of advancements, challenges, and future directions","authors":"Xi Chen,&nbsp;Pengfei Jin,&nbsp;Haiyan Mai,&nbsp;Shuhong Liang,&nbsp;Yaodong Ping,&nbsp;Chen Wang,&nbsp;Yingbo Zhao","doi":"10.1016/j.ipha.2026.04.003","DOIUrl":"10.1016/j.ipha.2026.04.003","url":null,"abstract":"<div><div>The integration of artificial intelligence (AI) into healthcare is reshaping medical disciplines, with hospital pharmacy undergoing a significant paradigm shift from a labor-intensive model to an intelligence-driven one. This comprehensive review examines the transformative role of AI in pharmaceutical administration and clinical pharmacy, synthesizing recent advancements, identifying key challenges, and projecting future directions. In pharmacy management, AI optimizes procurement through intelligent platforms, enhances dispensing accuracy and safety via automated systems and robotic technologies, and revolutionizes pharmacovigilance by shifting from spontaneous reporting to proactive, data-driven signal detection using machine learning (ML) and natural language processing (NLP). In clinical practice, AI-powered clinical decision support systems (AI-CDSS) augment clinician judgment by enabling real-time data analysis and improving therapeutic outcomes, while human-AI collaborative pre-prescription review systems significantly enhance medication safety. Furthermore, AI facilitates personalized medicine through the integration of pharmacogenomics and leverages large language models (LLMs) to improve patient engagement and medication adherence. Crucially, this review argues that AI is not a replacement for pharmacists but a catalyst for redefining their professional roles, elevating them from dispensers to clinical decision-makers and multidisciplinary collaborators. Despite its vast potential, the widespread adoption of AI faces significant hurdles, including poor data quality and interoperability, algorithmic “black-box” issues that undermine trust, ethical and privacy concerns, lagging regulatory frameworks, and a lack of long-term economic validation. Looking ahead, the future of intelligent pharmacy will be shaped by the integration of LLMs with knowledge graphs, the rise of explainable AI (XAI), the implementation of federated learning for secure data sharing, and the establishment of end-to-end digital ecosystems. Ultimately, AI is poised to become an indispensable collaborator in pharmacy, fostering a more efficient, intelligent, and patient-centered ecosystem.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 3","pages":"Pages 235-244"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic investigation of the Qizao Baoxin Formula in alleviating trastuzumab-induced cardiotoxicity via regulation of ferroptosis: A network pharmacology and molecular docking approach","authors":"Xintong Liu,&nbsp;Qiong Gu,&nbsp;Xiaoan Feng,&nbsp;Linlin Fan,&nbsp;Jing Xu,&nbsp;Chunyu Li,&nbsp;Guohui Li","doi":"10.1016/j.ipha.2026.04.002","DOIUrl":"10.1016/j.ipha.2026.04.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the active components and mechanisms of Qizao Baoxin Formula (QBF) in improving trastuzumab-induced cardiotoxicity (TIC) via ferroptosis regulation using network pharmacology and molecular docking.</div></div><div><h3>Methods</h3><div>The components of QBF were got from TCMSP 2.0, Herb 2.0, SymMap 2.0, ETCM 2.0, and BATMAN-TCM 2.0 five traditional Chinese medicine databases and screened using SwissADME. Targets were obtained from TCMSP and SwissTargetPrediction. Targets related to TIC were got from GeneCards, PubMed, and the Gene Expression Omnibus (GSE264120). Targets related to ferroptosis were obtained from FerrDb. Venny was applied to obtain the intersection targets. The Protein-Protein Interaction was constucted to investigate protein interactions and identify core targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were made to explore functions and pathways. A “Chinese Medicine-Component-Target” network was made to identify core components. Molecular docking was performed to validate interactions.</div></div><div><h3>Results</h3><div>A total of 1,690 QBF-related targets, 856 TIC-related targets, and 969 targets related to ferroptosis were identified, yielding 52 intersection targets. PPI network analysis identified 25 core targets, including BCL2, HIF1A, NFE2L2, and more. Enrichment analysis revealed significant involvement in oxidative stress, the FoxO signaling pathway, and more. The “Chinese Medicine-Component-Target” network analysis identified 268 core components, six main components of which exhibited strong binding affinity to BCL2, HIF1A, and NFE2L2.</div></div><div><h3>Conclusions</h3><div>QBF may target BCL2, HIF1A, and NFE2L2 via its core components to regulate oxidative stress, modulate ferroptosis, and alleviate TIC. These findings provide a scientific basis for further experimentation investigating QBF-mediated modulation of ferroptosis in TIC treatment.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 3","pages":"Pages 226-234"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and empirical validation of a competency-based evaluation index system for standardized residency training","authors":"Chang You,&nbsp;Yan Shen","doi":"10.1016/j.ipha.2026.04.004","DOIUrl":"10.1016/j.ipha.2026.04.004","url":null,"abstract":"<div><h3>Background</h3><div>Standardized residency training (SRT) is a core component of postgraduate medical education, and its quality is closely linked to residents' clinical performance. Currently, research on residents' post competency in China is limited, with a lack of comprehensive evaluation standards.</div></div><div><h3>Objectives</h3><div>To establish a competency-based evaluation index system for SRT and verify its effectiveness in predicting training outcomes.</div></div><div><h3>Methods</h3><div>This study integrated literature analysis, expert survey, and analytic hierarchy process (AHP) to construct the evaluation index system. AHP was used for weight assignment, with MATLAB software calculating indicator weights. Questionnaire surveys were conducted among residents from four departments for empirical validation, and <em>t</em>-test (SPSS 23.0) was used for statistical analysis.</div></div><div><h3>Results</h3><div>The index system included 5 first-level and 24 second-level indicators. The consistency ratio of AHP was 0.0201 (&lt;0.1), confirming reasonable weight assignment, with \"Competency improvement\" having the highest weight (0.3852). <em>T</em>-test results showed no statistically significant differences between predicted and actual scores (all <em>P</em> &gt; 0.05), and expert satisfaction was above 9.0.</div></div><div><h3>Conclusions</h3><div>The constructed index system is scientific and practical, effectively predicting SRT outcomes, and can provide a basis for optimizing residency training models.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 3","pages":"Pages 245-250"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the mechanism of action of Huoxue Quyu San hot package in intervening in sequelae of pelvic inflammatory disease based on network pharmacology and molecular docking","authors":"Hao Wang,&nbsp;Yuelin Huang,&nbsp;Yongfen Ding,&nbsp;Min Min,&nbsp;Haoran Li,&nbsp;Ruolan Zhang,&nbsp;Suyang Ma,&nbsp;Haoxiang Li,&nbsp;Xinrui Men,&nbsp;Liqun Yu","doi":"10.1016/j.ipha.2026.04.006","DOIUrl":"10.1016/j.ipha.2026.04.006","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the therapeutic mechanism of Huoxue Quyu San Reyan Bao in treating sequelae of pelvic inflammatory disease (SPID) using network pharmacology and molecular docking.</div></div><div><h3>Methods</h3><div>Active components and targets of Huoxue Quyu San were obtained from TCMSP, HERB, and UniProt. SPID-related targets were retrieved from GeneCards and OMIM. Common targets were identified via Venny 2.1.0, and a herb-component-target-pathway-disease network was constructed using Cytoscape 3.10.0. A PPI network was built using STRING to screen core targets. GO and KEGG enrichment analyses were performed using DAVID. Molecular docking was conducted using AutoDock Vina 1.5.7 to validate binding affinities.</div></div><div><h3>Results</h3><div>A total of 170 active components and 154 common targets were identified. Key components included quercetin, apigenin, baicalein, luteolin, and daidzein. Core targets were AKT1, TNF, IL-6, INS, IL-1β, and TP53. Involved pathways included cancer, TNF, PI3K-Akt, AGE-RAGE in diabetic complications, IL-17, lipid/atherosclerosis, C-type lectin receptor, and fluid shear stress/atherosclerosis pathways. Molecular docking showed strong binding affinities.</div></div><div><h3>Conclusions</h3><div>Huoxue Quyu San treats SPID by modulating TNF, PI3K-Akt, and AGE-RAGE pathways, exerting anti-inflammatory, antioxidant, microcirculation-improving, and apoptosis-inducing effects.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"4 3","pages":"Pages 251-259"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}